Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$180.53
+2.0%
$197.05
$153.58
$218.66
$319.35B0.556.02 million shs8.77 million shs
Credit Suisse Group AG stock logo
CS
Credit Suisse Group
$0.89
$0.89
$0.82
$6.36
$2.77B1.2737.84 million shsN/A
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
$132.30
-0.8%
$139.70
$124.10
$150.45
$43.88B0.372.12 million shs2.71 million shs
SVB Financial Group stock logo
SIVB
SVB Financial Group
$0.01
$0.01
$39.40
$597.16
$355K1.571.90 million shs934 shs
Stanley Black & Decker, Inc. stock logo
SWK
Stanley Black & Decker
$61.96
+4.8%
$74.46
$53.91
$110.88
$9.58B1.141.77 million shs1.95 million shs
UBS Group AG stock logo
UBS
UBS Group
$29.82
+2.5%
$31.16
$25.75
$35.84
$95.62B1.162.26 million shs2.75 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+1.83%+4.49%-10.24%+6.16%+7.57%
Credit Suisse Group AG stock logo
CS
Credit Suisse Group
0.00%0.00%0.00%0.00%0.00%
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
-0.98%-7.28%-3.40%+3.04%-3.98%
SVB Financial Group stock logo
SIVB
SVB Financial Group
0.00%0.00%0.00%0.00%-88.00%
Stanley Black & Decker, Inc. stock logo
SWK
Stanley Black & Decker
+4.66%+8.55%-22.97%-29.76%-31.36%
UBS Group AG stock logo
UBS
UBS Group
+2.47%+6.65%-11.43%-15.75%+8.97%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.9081 of 5 stars
3.45.04.23.93.92.51.3
Credit Suisse Group AG stock logo
CS
Credit Suisse Group
N/AN/AN/AN/AN/AN/AN/AN/A
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
4.5316 of 5 stars
2.15.05.02.53.12.51.3
SVB Financial Group stock logo
SIVB
SVB Financial Group
N/AN/AN/AN/AN/AN/AN/AN/A
Stanley Black & Decker, Inc. stock logo
SWK
Stanley Black & Decker
4.6334 of 5 stars
3.23.04.21.93.91.71.9
UBS Group AG stock logo
UBS
UBS Group
3.2164 of 5 stars
0.04.01.70.03.30.03.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.85
Moderate Buy$211.1916.98% Upside
Credit Suisse Group AG stock logo
CS
Credit Suisse Group
0.00
N/AN/AN/A
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
2.15
Hold$145.089.66% Upside
SVB Financial Group stock logo
SIVB
SVB Financial Group
0.00
N/AN/AN/A
Stanley Black & Decker, Inc. stock logo
SWK
Stanley Black & Decker
2.30
Hold$102.2064.95% Upside
UBS Group AG stock logo
UBS
UBS Group
2.33
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest KMB, ABBV, SWK, SIVB, UBS, and CS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/24/2025
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$139.00 ➝ $135.00
4/23/2025
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$165.00 ➝ $162.00
4/23/2025
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$158.00 ➝ $156.00
4/23/2025
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$168.00 ➝ $155.00
4/22/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$210.00
4/17/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$214.00 ➝ $214.00
4/17/2025
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$134.00 ➝ $146.00
4/17/2025
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$165.00 ➝ $165.00
4/17/2025
UBS Group AG stock logo
UBS
UBS Group
Keefe, Bruyette & Woods
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeModerate Sell ➝ Hold
4/11/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/11/2025
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderweight ➝ Underweight$124.00 ➝ $131.00
(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$56.33B5.67$13.34 per share13.53$1.90 per share95.02
Credit Suisse Group AG stock logo
CS
Credit Suisse Group
$22.88B0.12$0.25 per share3.51$15.26 per share0.06
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
$19.75B2.22$9.25 per share14.30$2.94 per share45.00
SVB Financial Group stock logo
SIVB
SVB Financial Group
$6.21B0.00N/AN/AN/A
Stanley Black & Decker, Inc. stock logo
SWK
Stanley Black & Decker
$15.37B0.62$5.58 per share11.10$56.47 per share1.10
UBS Group AG stock logo
UBS
UBS Group
$45.35B2.11$2.46 per share12.10$26.69 per share1.12
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.28B$2.4075.2212.911.627.59%296.28%12.65%4/25/2025 (Estimated)
Credit Suisse Group AG stock logo
CS
Credit Suisse Group
-$7.64B$0.651.37N/A15.12%23.83%1.81%N/A
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
$2.55B$7.3417.5216.794.4612.69%201.43%14.45%N/A
SVB Financial Group stock logo
SIVB
SVB Financial Group
N/A$25.350.00N/AN/AN/AN/AN/A
Stanley Black & Decker, Inc. stock logo
SWK
Stanley Black & Decker
$294.30M$1.9431.949.851.331.92%7.50%2.91%4/30/2025 (Estimated)
UBS Group AG stock logo
UBS
UBS Group
$5.09B$1.5219.629.87N/A6.93%5.93%0.32%4/30/2025 (Estimated)

Latest KMB, ABBV, SWK, SIVB, UBS, and CS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2025Q1 2025
Stanley Black & Decker, Inc. stock logo
SWK
Stanley Black & Decker
$0.68N/AN/AN/A$3.73 billionN/A
4/30/2025Q1 2025
UBS Group AG stock logo
UBS
UBS Group
$0.42N/AN/AN/A$10.19 billionN/A
4/25/2025Q1 2025
AbbVie Inc. stock logo
ABBV
AbbVie
$2.51N/AN/AN/A$12.91 billionN/A
4/22/2025Q1 2025
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
$1.89$1.93+$0.04$1.70$4.90 billion$4.84 billion
2/5/2025Q4 2024
Stanley Black & Decker, Inc. stock logo
SWK
Stanley Black & Decker
$1.28$1.49+$0.21$1.28$3.58 billionN/A
2/4/2025Q4 2024
UBS Group AG stock logo
UBS
UBS Group
$0.31$0.23-$0.08$0.23$10.90 billion$11.06 billion
1/31/2025Q4 2024
AbbVie Inc. stock logo
ABBV
AbbVie
$2.98$2.16-$0.82-$0.02$14.81 billionN/A
1/28/2025Q4 2024
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
$1.50$1.50N/A$1.34$4.87 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.563.63%+6.04%273.33%53 Years
Credit Suisse Group AG stock logo
CS
Credit Suisse Group
$0.055.62%N/A7.69%N/A
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
$5.043.81%+2.29%68.66%54 Years
SVB Financial Group stock logo
SIVB
SVB Financial Group
N/AN/AN/AN/AN/A
Stanley Black & Decker, Inc. stock logo
SWK
Stanley Black & Decker
$3.285.29%+3.04%169.07%58 Years
UBS Group AG stock logo
UBS
UBS Group
$0.220.74%+23.68%14.47%N/A

Latest KMB, ABBV, SWK, SIVB, UBS, and CS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/13/2025
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.643.4%4/15/20254/15/20255/15/2025
2/4/2025
UBS Group AG stock logo
UBS
UBS Group
annual$0.902.1%4/16/20254/16/20254/17/2025
1/28/2025
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
quarterly$1.263.84%3/7/20253/7/20254/2/2025
2/18/2025
Stanley Black & Decker, Inc. stock logo
SWK
Stanley Black & Decker
quarterly$0.823.77%3/4/20253/4/20253/18/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
17.94
0.66
0.55
Credit Suisse Group AG stock logo
CS
Credit Suisse Group
2.79
1.53
1.53
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
7.05
0.80
0.54
SVB Financial Group stock logo
SIVB
SVB Financial Group
N/AN/AN/A
Stanley Black & Decker, Inc. stock logo
SWK
Stanley Black & Decker
0.64
1.30
0.37
UBS Group AG stock logo
UBS
UBS Group
3.76
1.06
1.05

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Credit Suisse Group AG stock logo
CS
Credit Suisse Group
11.20%
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
76.29%
SVB Financial Group stock logo
SIVB
SVB Financial Group
92.35%
Stanley Black & Decker, Inc. stock logo
SWK
Stanley Black & Decker
87.77%
UBS Group AG stock logo
UBS
UBS Group
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.76 billionOptionable
Credit Suisse Group AG stock logo
CS
Credit Suisse Group
50,4803.11 billionN/AOptionable
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
44,000331.65 million329.63 millionOptionable
SVB Financial Group stock logo
SIVB
SVB Financial Group
N/A59.20 millionN/AN/A
Stanley Black & Decker, Inc. stock logo
SWK
Stanley Black & Decker
54,200154.54 million153.64 millionOptionable
UBS Group AG stock logo
UBS
UBS Group
72,6003.21 billion3.17 billionOptionable

Recent News About These Companies

UBS: Choose Your Instrument
UBS: Choose Your Instrument
UBS positive on U.S. equities, neutral on Europe
New Analyst Forecast: $GNTX Given 'Buy' Rating
UBS analysts expect USD/CHF to trade in 0.80-0.85 range
UBS cuts USD/JPY forecast. Here's the new target
New Analyst Forecast: $SUUN Given 'Buy' Rating
UBS Upgrades Healthcare Services Group (HCSG)
UBS nearing push into $1.6T private credit market

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie stock logo

AbbVie NYSE:ABBV

$180.53 +3.48 (+1.97%)
Closing price 04/24/2025 03:59 PM Eastern
Extended Trading
$187.79 +7.26 (+4.02%)
As of 08:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Credit Suisse Group stock logo

Credit Suisse Group NYSE:CS

$0.89 0.00 (0.00%)
As of 06/13/2023

Credit Suisse Group AG is a holding company, which engages in the provision of financial services. It operates through the following four divisions: Wealth Management, Investment Bank, Swiss Bank and Asset Management and four geographic regions: Switzerland, Europe, the Middle East and Africa (EMEA), Asia Pacific, and Americas. The Wealth Management division offers comprehensive wealth management and investment solutions, tailored financing, and advisory services to ultra-high-net-worth (UHNW) and high net-worth (HNW) individuals and external asset managers. The Investment Bank division offers a broad range of financial products and services focused on client-driven businesses and also supports Credit Suisse's Wealth Management division and its clients. The Swiss Bank division offers comprehensive advice and a wide range of financial solutions to private, corporate, and institutional clients in Switzerland. The Asset Management division offers investment solutions and services globally to a broad range of clients, including pension funds, governments, foundations and endowments, corporations, and individuals. The company was founded by Alfred Escher on July 5, 1856 and is headqua

Kimberly-Clark stock logo

Kimberly-Clark NYSE:KMB

$132.30 -1.10 (-0.82%)
Closing price 04/24/2025 03:59 PM Eastern
Extended Trading
$132.74 +0.44 (+0.33%)
As of 08:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products in the United States. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The company's Personal Care segment offers disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Thinx, Poise, Depend, Plenitud, Softex, and other brand names. Its Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The company's K-C Professional segment offers wipers, tissues, towels, apparel, personal protective equipment, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. It also sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to distributors, manufacturing, lodging, office building, food service, and public facilities, as well as through e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Stanley Black & Decker stock logo

Stanley Black & Decker NYSE:SWK

$61.96 +2.82 (+4.77%)
Closing price 04/24/2025 03:59 PM Eastern
Extended Trading
$61.66 -0.31 (-0.49%)
As of 08:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stanley Black & Decker, Inc. engages in the provision of power and hand tools, and related accessories, products, services and equipment for oil and gas, infrastructure applications, commercial electronic security and monitoring systems, healthcare solutions, and mechanical access solutions. It operates through the Tools and Outdoor and Industrial segments. The Tools and Outdoor segment refers to power tools, hand tools, accessories and storage, and outdoor power equipment product lines. The Industrial segment includes the engineered fastening and infrastructure businesses. The company was founded by Frederick T. Stanley in 1843 and is headquartered in New Britain, CT.

UBS Group stock logo

UBS Group NYSE:UBS

$29.82 +0.74 (+2.54%)
Closing price 04/24/2025 03:59 PM Eastern
Extended Trading
$29.90 +0.08 (+0.27%)
As of 08:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UBS Group AG provides financial advice and solutions to private, institutional, and corporate clients worldwide. It operates through five divisions: Global Wealth Management, Personal & Corporate Banking, Asset Management, Investment Bank, and Non-core and Legacy. The company offers investment advice, estate and wealth planning, investing, corporate and banking, and investment management, as well as mortgage, securities-based, and structured lending solutions. It also provides personal banking products and services, such as deposits, credit and debit cards, and online and mobile banking, as well as lending, investments, retirement, and wealth management services; and corporate and institutional solutions, including equity and debt capital markets, syndicated and structured credit, private placements, leasing, traditional financing, and transaction banking solutions for payment and cash management services, trade and export finance, and global custody solutions. In addition, the company offers equities, fixed income, hedge funds, real estate and private markets, indexed and alternative beta strategies, asset allocation and currency investment strategies, customized multi-asset solutions, advisory and fiduciary services, and multi-manager hedge fund solutions and advisory services. Further, it advises clients on strategic business opportunities and helps them raise capital to fund their activities; enables its clients to buy, sell, and finance securities on capital markets and to manage their risks and liquidity; distributes, trades in, finances, and clears cash equities and equity-linked products; structures, originates, and distributes new equity and equity-linked issues; and originates, distributes, manages risk, and provides liquidity in foreign exchange, rates, credit and precious metals. The company was formerly known as UBS AG and changed its name to UBS Group AG in December 2014. UBS Group AG was founded in 1862 and is headquartered in Zurich, Switzerland.